Vanguard Global Advisers
AURA icon

Vanguard Global Advisers’s Aura Biosciences AURA Stock Holding History

Vanguard Global Advisers’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Sell
37,682
-2,107
-5% -$15.1K ﹤0.01% 2380
2026
Q1 		$266K Buy
+39,789
New +$228K ﹤0.01% 2300

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Global Advisers's AURA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Aura Biosciences (AURA) stake by 5.3% in Q2 2026, selling an estimated $15.1K and leaving 37,682 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Vanguard Global Advisers first reported a position in AURA in Q1 2026 and has held it in 2 quarters since. 145 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Vanguard Global Advisers held 37,682 shares of Aura Biosciences worth $268K as of Q2 2026.
  • Vanguard Global Advisers sold 2,107 Aura Biosciences shares in Q2 2026, an estimated $15.1K.
  • Aura Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2380 holding.
  • Vanguard Global Advisers first reported a position in Aura Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 145 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.